Edgewise Therapeutics
Abby Bronson, MBA, joined Edgewise Therapeutics in April 2020 as our Vice President of Patient Advocacy and External Innovation. Abby has recent experience as the SVP of Research Strategy at Parent Project Muscular Dystrophy where she managed the research portfolio and developed novel trial strategies to accelerate the clinical trial process in Duchenne. Prior to PPMD she was the Director of Operations at the Division of Clinical Innovation at NCATS, NIH. She has also had senior positions at MedImmune and Children’s National Medical Center. She holds an MBA from the Wharton School of Business at the University of Pennsylvania and a BA from the University of Vermont.
This person is not in any offices
Edgewise Therapeutics
1 followers
Edgewise Therapeutics is a biotechnology company harnessing proven expertise and understanding of skeletal muscle physiology to develop novel, transformative therapies for serious muscle diseases. Based in Boulder, Colorado, we have built a state-of-the-art muscle research facility to capitalize on new insights into the nature and consequences of muscle adaptation and injury with disease. Edgewise recently closed it’s Series B financing round which will support the advancement of Edgewise Therapeutic’s lead product candidate into clinical development for Duchenne and Becker Muscular Dystrophy (DMD and BMD) as well as expansion of the company’s pipeline. The company’s leadership team has founded multiple biotechnology startups, several of which have gone on to become publicly-traded companies and brings to bear a depth of experience in drug discovery, development and commercialization.